Parainfluenza virus type 3 infections in a hematology unit.
Parainfluenza virus type 3 (PIV3) is associated with a high mortality rate in BMT recipients with lower respiratory tract infections. We describe nine patients with hematological malignancies (five having undergone either allogeneic or autologous stem cell transplantation) identified as having PIV3 infection during a 2-month period in a Hematology Unit. Four patients with infiltrates on chest radiograph received intravenous ribavirin therapy; all survived. The infection was community-acquired in two patients, while nosocomial origin of the disease was evident, or presumed, in the remaining seven. The policy implemented to control the spread of PIV3 was as follows: (1) nasopharyngeal samples for antigen detection were obtained from all patients presenting with respiratory symptoms; (2) all diagnosed (or suspected) PIV3-positive hematological patients were nursed following contact isolation precautions, preferably in the Infectious Diseases Unit; and (3) staff were given further education on hospital hygiene. Our experience shows that it may be possible to avoid mortality for PIV3 lower respiratory tract infection in immunocompromised patients by early commencement of intravenous ribavirin. It is also possible, even without closing the ward, to contain nosocomial spread of PIV3 by implementing systematic nasopharyngeal sampling for rapid diagnostics, and by strict adherence to cohorting and contact isolation precautions.
Hohenthal
U
U
Department of Medicine, Turku University Central Hospital, Finland.
Nikoskelainen
J
J
Vainionpää
R
R
Peltonen
R
R
Routamaa
M
M
Itälä
M
M
Kotilainen
P
P
D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000032:analysis; D003428:Cross Infection / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000150:complications*; D006405:Hematology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006757:Hospital Units / Q000592:standards*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D010224:Parainfluenza Virus 3, Human / Q000187:drug effects / Q000276:immunology; D018184:Paramyxoviridae Infections / Q000175:diagnosis / Q000517:prevention & control / Q000635:transmission*; D012254:Ribavirin / Q000008:administration & dosage / Q000592:standards
D000956:Antigens, Viral; D012254:Ribavirin